An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo

Infection and Immunity

Volumn 82, Issue 10, 2014, Pages 4080-4091

  Baliban, Scott M ^a   Michael, Amanda ^a   Shammassian, Berje ^a   Mudakha, Shikata ^a   Khan, Amir S ^b   Cocklin, Simon ^a   Zentner, Isaac ^a   Latimer, Brian P ^a   Bouillaut, Laurent ^c   Hunter, Meredith ^d   Marx, Preston ^d   Sardesai, Niranjan Y ^b   Welles, Seth L ^a   Jacobson, Jeffrey M ^a   Weiner, David B ^e   Kutzler, Michele A ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Division of Infectious Diseases and HIV Medicine Department of Medicine Drexel University College of Medicine ^*  (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TULANE UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; DNA VACCINE; NEUTRALIZING ANTIBODY; SYNTHETIC DNA; TOXIN ANTIBODY; ANTITOXIN; BACTERIAL PROTEIN; BACTERIAL TOXIN; ENTEROTOXIN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL SPORE; CARBOXY TERMINAL RECEPTOR BINDING DOMAIN; CARBOXY TERMINAL SEQUENCE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DNA IMMUNIZATION; DRUG BINDING SITE; DRUG EFFICACY; ELECTROPORATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PROTEIN DOMAIN; ANIMAL; BLOOD; C57BL MOUSE; CROSS PROTECTION; ELECTROPHORESIS; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; RHESUS MONKEY; SERODIAGNOSIS; SURVIVAL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTITOXINS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL VACCINES; CROSS PROTECTION; ELECTROPHORESIS; ENTEROTOXINS; FEMALE; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 84907095606     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01950-14     Document Type: Article

References (70)

1. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7:526-536. http://dx.doi.org/10.1038/nrmicro2164.
2. McDonald LC, Killgore GE, Thompson A, Owens RC, Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. 2005. An epidemic, toxin genevariant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441. http://dx.doi.org/10.1056/NEJMoa051590.
3. Bartlett JG. 2002. Clostridium difficile-associated enteric disease. Curr. Infect. Dis. Rep. 4:477-483. http://dx.doi.org/10.1007/s11908-002-0032-0.
4. Redelings MD, Sorvillo F, Mascola L. 2007. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg. Infect. Dis. 13:1417-1419. http://dx.doi.org/10.3201/eid1309.061116.
5. Carter GP, Rood JI, Lyras D. 2010. The role of toxin A and toxin B in Clostridium difficile-associated disease: past and present perspectives. Gut Microbes 1:58-64. http://dx.doi.org/10.4161/gmic.1.1.10768.
6. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713. http://dx.doi.org/10.1038/nature09397.
7. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179. http://dx.doi.org/10.1038/nature07822.
8. Lyerly DM, Krivan HC, Wilkins TD. 1988. Clostridium difficile: its disease and toxins. Clin. Microbiol. Rev. 1:1-18.
9. Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP. 2003. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect. Immun. 71:1608-1610. http://dx.doi.org/10.1128/IAI.71.3.1608-1610.2003.
10. Kink JA, Williams JA. 1998. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect. Immun. 66:2018-2025.
11. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. 2010. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965-969. http://dx.doi.org/10.1016/j.vaccine.2009.10.144.
12. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74:6339-6347. http://dx.doi.org/10.1128/IAI.00982-06.
13. Kim PH, Iaconis JP, Rolfe RD. 1987. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect. Immun. 55:2984-2992.
14. Greco A, Ho JG, Lin SJ, Palcic MM, Rupnik M, Ng KK. 2006. Carbohydrate recognition by Clostridium difficile toxin A. Nat. Struct. Mol. Biol. 13:460-461. http://dx.doi.org/10.1038/nsmb1084.
15. Olling A, Goy S, Hoffmann F, Tatge H, Just I, Gerhard R. 2011. The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin A. PLoS One 6:e17623. http://dx.doi.org/10.1371/journal.pone.0017623.
16. Lyerly DM, Phelps CJ, Toth J, Wilkins TD. 1986. Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect. Immun. 54:70-76.
17. Frey SM, Wilkins TD. 1992. Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect. Immun. 60:2488-2492.
18. Sauerborn M, Leukel P, von Eichel-Streiber C. 1997. The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. FEMS Microbiol. Lett. 155:45-54. http://dx.doi.org/10.1111/j.1574 -6968.1997.tb12684.x.
19. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205. http://dx.doi.org/10.1056/NEJMoa0907635.
20. Hokey DA, Weiner DB. 2006. DNA vaccines for HIV: challenges and opportunities. Springer Semin. Immunopathol. 28:267-279. http://dx.doi.org/10.1007/s00281-006-0046-z.
21. Kutzler MA, Weiner DB. 2008. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9:776-788. http://dx.doi.org/10.1038/nrg2432.
22. Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. 2009. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 27:3598-3604. http://dx.doi.org/10.1016/j.vaccine.2009.03.058.
23. Jin K, Wang S, Zhang C, Xiao Y, Lu S, Huang Z. 2013. Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B. Hum. Vaccin. Immunother. 9:63-73. http://dx.doi.org/10.4161/hv.22434.
24. Weeks SD, Drinker M, Loll PJ. 2007. Ligation independent cloning vectors for expression of SUMO fusions. Protein Expr. Purif. 53:40-50. http://dx.doi.org/10.1016/j.pep.2006.12.006.
25. Zentner I, Sierra LJ, Fraser AK, Maciunas L, Mankowski MK, Vinnik A, Fedichev P, Ptak RG, Martin-Garcia J, Cocklin S. 2013. Identification of a small-molecule inhibitor of HIV-1 assembly that targets the phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix protein. ChemMedChem 8:426-432. http://dx.doi.org/10.1002/cmdc.201200577.
26. Slifka MK, Ahmed R. 1996. Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay. J. Immunol. Methods 199:37-46. http://dx.doi.org/10.1016/S0022-1759(96)00146-9.
27. Brown KA, Kriss JA, Moser CA, Wenner WJ, Offit PA. 2000. Circulating rotavirus-specific antibody-secreting cells (ASCs) predict the presence of rotavirus-specific ASCs in the human small intestinal lamina propria. J. Infect. Dis. 182:1039-1043. http://dx.doi.org/10.1086/315808.
28. Crotty S, Aubert RD, Glidewell J, Ahmed R. 2004. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods 286:111-122. http://dx.doi.org/10.1016/j.jim.2003.12.015.
29. Qadri F, Ryan ET, Faruque AS, Ahmed F, Khan AI, Islam MM, Akramuzzaman SM, Sack DA, Calderwood SB. 2003. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect. Immun. 71:4808-4814. http://dx.doi.org/10.1128/IAI.71.8.4808-4814.2003.
30. Ogawa T, Tarkowski A, McGhee ML, Moldoveanu Z, Mestecky J, Hirsch HZ, Koopman WJ, Hamada S, McGhee JR, Kiyono H. 1989. Analysis of human IgG and IgA subclass antibody-secreting cells from localized chronic inflammatory tissue. J. Immunol. 142:1150-1158.
31. Mestecky J, Jackson S, Moldoveanu Z, Nesbit LR, Kulhavy R, Prince SJ, Sabbaj S, Mulligan MJ, Goepfert PA. 2004. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res. Hum. Retrovir. 20:972-988. http://dx.doi.org/10.1089/aid.2004.20.972.
32. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficileassociated disease. Gastroenterology 135:1984-1992. http://dx.doi.org/10.1053/j.gastro.2008.09.002.
33. Sorg JA, Dineen SS. 2009. Laboratory maintenance of Clostridium difficile. Curr. Protoc. Microbiol. Chapter 9:Unit9A 1. http://dx.doi.org/10.1002/9780471729259.mc09a01s12.
34. Frisch C, Gerhard R, Aktories K, Hofmann F, Just I. 2003. The complete receptor-binding domain of Clostridium difficile toxin A is required for endocytosis. Biochem. Biophys. Res. Commun. 300:706-711. http://dx.doi.org/10.1016/S0006-291X(02)02919-4.
35. Florin I, Thelestam M. 1986. Lysosomal involvement in cellular intoxication with Clostridium difficile toxin B. Microb. Pathog. 1:373-385. http://dx.doi.org/10.1016/0882-4010(86)90069-0.
36. Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM, Wilkins TD, Johnson JL. 1990. Molecular characterization of the Clostridium difficile toxin A gene. Infect. Immun. 58:480-488.
37. von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, Schulze J, Sauerborn M. 1992. Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol. Gen. Genet. 233:260-268. http://dx.doi.org/10.1007/BF00587587.
38. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193. http://dx.doi.org/10.1016/S0140-6736(00)03592-3.
39. Katchar K, Taylor CP, Tummala S, Chen X, Sheikh J, Kelly CP. 2007. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin. Gastroenterol. Hepatol. 5:707-713. http://dx.doi.org/10.1016/j.cgh.2007.02.025.
40. Gill DM. 1982. Bacterial toxins: a table of lethal amounts. Microbiol. Rev. 46:86-94.
41. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. 2011. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC Infect. Dis. 11:194. http://dx.doi.org/10.1186/1471-2334-11-194.
42. Kyne L, Hamel MB, Polavaram R, Kelly CP. 2002. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34:346-353. http://dx.doi.org/10.1086/338260.
43. Blondeau JM. 2009. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J. Antimicrob. Chemother. 63:238-242. http://dx.doi.org/10.1093/jac/dkn477.
44. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247-263. http://dx.doi.org/10.1128/CMR.18.2.247-263.2005.
45. Stavnezer J. 1996. Immunoglobulin class switching. Curr. Opin. Immunol. 8:199-205. http://dx.doi.org/10.1016/S0952-7915(96)80058-6.
46. Xing X, Sha S, Li Y, Zong L, Jiang T, Cao Y. 2012. Immunization with a new DNA vaccine for Alzheimer's disease elicited Th2 immune response in BALB/c mice by in vivo electroporation. J. Neurol. Sci. 313:17-21. http://dx.doi.org/10.1016/j.jns.2011.09.040.
47. Wu CJ, Lee SC, Huang HW, Tao MH. 2004. In vivo electroporation of skeletal muscles increases the efficacy of Japanese encephalitis virus DNA vaccine. Vaccine 22:1457-1464. http://dx.doi.org/10.1016/j.vaccine.2003.10.011.
48. Rath A, Batra D, Kaur R, Vrati S, Gupta SK. 2003. Characterization of immune response in mice to plasmid DNA encoding dog zona pellucida glycoprotein-3. Vaccine 21:1913-1923. http://dx.doi.org/10.1016/S0264 -410X(02)00824-1.
49. Tollefsen S, Tjelle T, Schneider J, Harboe M, Wiker H, Hewinson G, Huygen K, Mathiesen I. 2002. Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine 20:3370-3378. http://dx.doi.org/10.1016/S0264-410X(02)00289-X.
50. Taylor NS, Thorne GM, Bartlett JG. 1981. Comparison of two toxins produced by Clostridium difficile. Infect. Immun. 34:1036-1043.
51. Jawa RS, Mercer DW. 2012. Clostridium difficile-associated infection: a disease of varying severity. Am. J. Surg. 204:836-842. http://dx.doi.org/10 .1016/j.amjsurg.2012.05.025.
52. Cunney RJ, Magee C, McNamara E, Smyth EG, Walshe J. 1998. Clostridium difficile colitis associated with chronic renal failure. Nephrol. Dial. Transplant. 13:2842-2846. http://dx.doi.org/10.1093/ndt/13.11 .2842.
53. Dobson G, Hickey C, Trinder J. 2003. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med. 29:1030. http://dx.doi.org/10.1007/s00134-003-1754-7.
54. Jacob SS, Sebastian JC, Hiorns D, Jacob S, Mukerjee PK. 2004. Clostridium difficile and acute respiratory distress syndrome. Heart Lung 33: 265-268. http://dx.doi.org/10.1016/j.hrtlng.2004.04.003.
55. Johnson S, Kent SA, O'Leary KJ, Merrigan MM, Sambol SP, Peterson LR, Gerding DN. 2001. Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann. Intern. Med. 135:434-438. http://dx.doi.org/10.7326/0003-4819 -135-6-200109180-00012.
56. Sakurai T, Hajiro K, Takakuwa H, Nishi A, Aihara M, Chiba T. 2001. Liver abscess caused by Clostridium difficile. Scand. J. Infect. Dis. 33:69-70 http://dx.doi.org/10.1080/003655401750064112.
57. Hamm EE, Voth DE, Ballard JD. 2006. Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc. Natl. Acad. Sci. U. S. A. 103:14176-14181. http://dx.doi.org/10.1073/pnas.0604725103.
58. Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF, Cutting SM. 2011. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect. Immun. 79: 2295-2302. http://dx.doi.org/10.1128/IAI.00130-11.
59. O'Brien JB, McCabe MS, Athie-Morales V, McDonald GS, Ni Eidhin DB, Kelleher DP. 2005. Passive immunisation of hamsters against Clostridium difficile infection using antibodies to surface layer proteins. FEMS Microbiol. Lett. 246:199-205. http://dx.doi.org/10.1016/j.femsle.2005.04 .005.
60. Ni Eidhin DB, O'Brien JB, McCabe MS, Athie-Morales V, Kelleher DP. 2008. Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol. Med. Microbiol. 52: 207-218. http://dx.doi.org/10.1111/j.1574-695X.2007.00363.x.
61. Sandolo C, Pechine S, Monnier AL, Hoys S, Janoir C, Coviello T, Alhaique F, Collignon A, Fattal E, Tsapis N. 2011. Encapsulation of Cwp84 into pectin beads for oral vaccination against Clostridium difficile. Eur. J. Pharm. Biopharm. 79:566-573. http://dx.doi.org/10.1016/j.ejpb .2011.05.011.
62. Pechine S, Deneve C, Le Monnier A, Hoys S, Janoir C, Collignon A. 2011. Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen. FEMS Immunol. Med. Microbiol. 63:73-81. http://dx.doi.org/10.1111/j.1574-695X.2011.00832.x.
63. Seregin SS, Aldhamen YA, Rastall DP, Godbehere S, Amalfitano A. 2012. Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine 30:1492-1501. http://dx.doi .org/10.1016/j.vaccine.2011.12.064.
64. Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, Nie W, Kumar R, Tzipori S, Wang J, Savidge T, Feng H. 2012. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect. Immun. 80:2678-2688. http://dx.doi.org/10.1128/IAI.00215-12.
65. Yang Z, Schmidt D, Liu W, Li S, Shi L, Sheng J, Chen K, Yu H, Tremblay JM, Chen X, Piepenbrink KH, Sundberg EJ, Kelly CP, Bai G, Shoemaker CB, Feng H. 2014. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J. Infect. Dis. 210:964-972. http://dx.doi.org/10.1093/infdis/jiu196.
66. Kuehne SA, Collery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP. 2014. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J. Infect. Dis. 209:83-86. http://dx .doi.org/10.1093/infdis/jit426.
67. Lanis JM, Heinlen LD, James JA, Ballard JD. 2013. Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog. 9:e1003523. http://dx.doi.org/10.1371/journal.ppat .1003523.
68. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan G, Wren BW. 2009. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol. 10:R102. http://dx.doi.org/10.1186/gb-2009-10-9-r102.
69. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, Fuchs J, Koblin B, Kim DH, Joseph P, Keefer MC, Baden LR, Eldridge J, Boyer J, Sherwat A, Cardinali M, Allen M, Pensiero M, Butler C, Khan AS, Yan J, Sardesai NY, Kublin JG, Weiner DB. 2013. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J. Infect. Dis. 208:818-829. http://dx.doi.org/10.1093/infdis/jit236.
70. Woodland DL. 2004. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25:98-104. http://dx.doi.org/10.1016/j.it .2003.11.009.